Cholestatic itch, a debilitating and persistent condition, has long vexed clinicians and patients alike due to its resistance to conventional treatments. This debilitating symptom severely diminishes quality of life, often leading to disrupted sleep, psychological distress, and social withdrawal. In an inspiring development from Peking University, a multidisciplinary team spearheaded by Professor Lei Xiaoguang has unveiled a novel small-molecule inverse agonist, HEP-50768, which specifically targets the G protein-coupled receptor MRGPRX4—identified as a central mediator of cholestatic itch.
At the molecular heart of cholestatic itch lies the intricate interplay between bile acid metabolites and sensory receptors on peripheral neurons. Previous landmark research from the team elucidated how 3-hydroxyl-sulfated bile acids serve as endogenous ligands that aberrantly activate MRGPRX4, a receptor densely expressed on itch-sensory neurons. This discovery unravelled a critical pathological signaling axis, thus offering a precise molecular target for therapeutic intervention—a target hitherto elusive in clinical practice.
This breakthrough is especially significant given the inadequacy of existing treatments. The currently employed agents such as ursodeoxycholic acid, which modifies bile acid composition, rifampin, and maralixibat, a bile acid transporter inhibitor, deliver inconsistent and often partial relief. Antihistamines and corticosteroids, classical modalities for itch of allergic origin, largely fail against cholestatic itch because histamine-independent pathways are at play. Hence, the development of antagonists specifically inhibiting MRGPRX4 represents a paradigm shift, harnessing receptor-level precision to counteract itch signals at their source.
The team embarked on an ambitious high-throughput screening campaign of over 100,000 small molecules to identify candidates capable of modulating MRGPRX4 with high specificity and potency. Following rigorous optimization guided by structure-activity relationships, HEP-50768 emerged as a potent inverse agonist. Unlike antagonists that simply block receptor activation by ligands, inverse agonists additionally suppress the receptor’s intrinsic constitutive activity, conferring enhanced therapeutic efficacy particularly in hyperactive receptor states.
To dissect the compound’s mechanism of action, the researchers utilized advanced cryo-electron microscopy, resolving the receptor-ligand complex at near-atomic resolution. Complementary computational simulations elucidated key binding interactions, revealing how HEP-50768 stabilizes MRGPRX4 in an inactive conformation, thereby precluding conformational transitions necessary for downstream signaling. This structural insight not only substantiates the inverse agonist mode but also provides a blueprint for further refinement of receptor-targeting molecules.
Preclinical pharmacological evaluation incorporated innovative humanized rodent models that express the human MRGPRX4 receptor. In these models, HEP-50768 significantly mitigated scratching behavior—an established surrogate for itch sensation—demonstrating both functional blockade and symptom amelioration. Pharmacokinetic profiling underscored favorable drug-like properties including adequate bioavailability, metabolic stability, and central nervous system penetration, aligning with the therapeutic objective of peripheral neuronal targeting without off-target effects.
Safety evaluation spanned rodent and non-human primate studies, where HEP-50768 exhibited a robust safety margin with no observable toxicity at therapeutic dose ranges. This favorable preclinical safety profile, coupled with efficacy data, lent credence to the translational potential of this compound. Consequently, the Investigational New Drug (IND) application has been submitted, paving the way for first-in-human Phase I clinical trials to assess safety, tolerability, and preliminary pharmacodynamics.
The implications of this research extend beyond cholestatic itch. Since MRGPRX4 is implicated in other chronic pruritic conditions, HEP-50768 or its derivatives might offer relief for a broader patient population suffering from intractable itch. The drug discovery model exemplified here—combining unbiased chemical screening, structural elucidation, and translational animal models—could serve as a template for tackling other sensory receptor-mediated diseases.
From a biomedical engineering perspective, this work exemplifies the power of integrative approaches merging chemistry, structural biology, pharmacology, and neuroscience to address a previously neglected clinical challenge. The development of a selective inverse agonist marks a new frontier in drug discovery aimed at modulating receptor conformations rather than mere blocking, enabling fine-tuned therapeutic modulation.
In summary, the evolution from mechanistic insight into bile acid–MRGPRX4 interaction to the design of a clinically viable therapeutic offers a beacon of hope for patients afflicted with cholestatic itch. By targeting the receptor responsible for the disease’s primary sensory symptom, HEP-50768 embodies precision medicine’s promise—delivering targeted, effective, and safe treatment options in a field long starved of innovation.
As this novel drug candidate advances into clinical evaluation, the scientific community watches with anticipation. Should HEP-50768’s promising preclinical profile translate into human efficacy, it could revolutionize the management paradigm of cholestatic and other chronic itch disorders, dramatically improving patient quality of life.
The publication of this seminal study in Nature Chemical Biology not only underscores the scientific rigor behind the discovery but also reflects the growing global emphasis on translational research that bridges fundamental biology and clinical innovation. This cross-institutional collaboration, involving PKU, Hepai-Tech Biopharma, USTC, and the Hefei Comprehensive National Science Center, exemplifies how converging expertise accelerates therapeutic breakthroughs.
Ultimately, the advent of HEP-50768 represents a milestone in the ongoing battle against chronic itch, transforming a debilitating invisible torment into a treatable condition. The precision targeting of MRGPRX4 opens new avenues for the design of next-generation itch therapeutics that promise efficacy where older treatments fall short, fostering optimism for millions worldwide.
Subject of Research: Development of a selective small-molecule inverse agonist targeting MRGPRX4 for cholestatic itch treatment
Article Title: Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment
News Publication Date: May 18, 2026
Web References:
PKU News – Original Article (Chinese)
DOI: 10.1038/s41589-026-02195-0
References:
Lei Xiaoguang et al., “Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment,” Nature Chemical Biology, 2026.
Keywords: Cholestatic itch, MRGPRX4, inverse agonist, bile acids, small-molecule drug, chronic itch, cryo-electron microscopy, pharmacology, drug discovery, translational research, receptor signaling, preclinical studies
Tags: bile acid metabolites and itchbile acid receptor signalingcholestatic itch treatmentchronic itch molecular targetsdrug development for liver disease symptomsHEP-50768 drug candidatehistamine-independent itch managementMRGPRX4 receptor antagonistnovel therapies for pruritusPeking University medical researchsensory neuron itch mechanismssmall-molecule inverse agonist
